PRESS RELEASE

Thursday, 6 September 2018 8.00 CET

Biovica strengthens the company with Market Access and QA Director

Biovica has recruited Wing Cheng as Market Access & QA Director. He will join Biovica on the 8th of October 2018. Wing has extensive experience in the regulatory and reimbursement area from different companies, national and international authorities.

He holds a Ph.D. in clinical immunology from Uppsala University. Wing is leaving the role as Manager Clinical Utility at Thermo Fisher. Wing also has background from national and European authorities in the regulatory and reimbursement area, e.g. The Dental and Pharmaceutical Benefits Agency, TLV, the Medical Products Agency, MPA, European Medicine Agency, EMA and the European Commission.

Wing will lead the work in market access and quality assurance for Biovica's product DiviTum®. He will be a part of the management team at Biovica.

"*I am impressed with Biovica's ambitions and what the company has achieved so far. DiviTum® will make a big difference for the world's cancer patients and is well positioned for the increasing amount of targeted treatments in the field. I'm really looking forward to contributing to the continued commercialization of DiviTum® and realizing the great potential of the company's products,*" said Wing Cheng.

"*I am very pleased that Wing Cheng will reinforce an already strong team. Wing's experience and expertise in the market access area will add great value to Biovica*" says Anders Rylander, CEO of Biovica International AB.

Contact

Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
E-mail: anders.rylander@biovica.com

Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE labelled and MPA registered.